Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
November 15 2018 - 10:40AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
SEC
File Number
000-13789
NOTIFICATION
OF LATE FILING
(Check
One)
:
|
[ ]
Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR
[ ] Form N-CSR
|
|
|
|
For
Period Ended:
September 30, 2018
|
|
[ ]
|
Transition
Report on Form 10-K
|
|
[ ]
|
Transition
Report on Form 20-F
|
|
[ ]
|
Transition
Report on Form 11-K
|
|
[ ]
|
Transition
Report on Form 10-Q
|
|
[ ]
|
Transition
Report on Form N-SAR
|
|
For
the Transition Period Ended:
|
|
|
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
PART
I — REGISTRANT INFORMATION
Adhera
Therapeutics, Inc.
Full
Name of Registrant
N/A
Former
Name if Applicable
4721
Emperor Boulevard, Suite 350
Address
of Principal Executive Office (Street and Number)
Durham,
NC 27703
City,
State and Zip Code
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate.)
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
|
[X]
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III - NARRATIVE
State
below in reasonable detail why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report portion thereof, could
not be filed within the prescribed time period. (Attach extra sheets if needed.)
The
compilation, dissemination and review of the information required to be presented in the Form 10-Q for the three and nine months
ended September 30, 2018 could not be completed and filed due to additional time required by the registrant to finalize its document
preparation and legal review.
The registrant anticipates it will file such report no later
than five days after its original prescribed due date.
PART
IV - OTHER INFORMATION
(1)
Name and telephone number of person to contact in regard to this notification
Eric
Teague
|
|
919
|
|
578-5901
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file
such report(s) been filed? If the answer is no, identify report(s). [X] Yes [ ] No
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the subject report or portion thereof? [ ] Yes [X] No
If
so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
Adhera
Therapeutics, Inc.
(Name
of Registrant as Specified in its Charter)
Has
caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date:
November 15, 2018
|
By:
|
/s/
Eric Teague
|
|
Name:
|
Eric
Teague
|
|
Title:
|
Chief
Financial Officer
|
Adhera Therapeutics (CE) (USOTC:ATRX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Adhera Therapeutics (CE) (USOTC:ATRX)
Historical Stock Chart
From Dec 2023 to Dec 2024